68 results
Page 3 of 4
8-K
uoj1jp
18 Dec 19
Entry into a Material Definitive Agreement
7:16am
8-K
EX-99.1
6lw5 qc66
17 Oct 19
Syros Announces Update on Selective CDK7 Inhibitor Portfolio
8:30am
424B5
dwj40zseclvpwf
8 Apr 19
Prospectus supplement for primary offering
12:00am
424B5
fblsdkd9zbmm ibw
8 Apr 19
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
w555uvf9jxymqdgolyj
8 Apr 19
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.2
9bd37qhr6u11wy9um
8 Apr 19
Entry into a Material Definitive Agreement
12:00am
424B5
cry9qjs1 c2daqgj
4 Apr 19
Prospectus supplement for primary offering
4:15pm
424B5
xtf2g430o
4 Apr 19
Prospectus supplement for primary offering
4:13pm
8-K
EX-99.2
4yf86x8jev0 zeedm
7 Jan 19
Regulation FD Disclosure
6:30am
8-K
EX-99.1
ko7ukf vgwiu
7 Jan 19
Regulation FD Disclosure
6:30am
8-K
EX-99.1
z6mlxp607o6usuoud
3 Dec 18
Syros Announces Promising Clinical Data from Ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients at ASH Annual Meeting
8:07am
8-K
EX-99.2
ygz5r4yl
15 Nov 18
Regulation FD Disclosure
4:03pm
8-K
72al tlex
26 Sep 18
Other Events
8:31am